Atjaunināt sīkdatņu piekrišanu

E-grāmata: Vaccine Development and Manufacturing

Edited by , Edited by , Edited by
Citas grāmatas par šo tēmu:
  • Formāts - PDF+DRM
  • Cena: 153,41 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Bibliotēkām
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

Citing vaccine development as a complex process requiring multiple clinical trials to demonstrate product safety, efficacy, purity, potency, and consistency in manufacturing, Wen, Ellis, and Pujar and their international expert contributors provide comprehensive information on the various fields involved in the production of vaccines from fermentation, purification and formation to regulatory filing and facility design. They aim for a book that will be useful for a broad cross-section of biotechnology professionals, medical and biomedical scientists, and health care professionals. There are 15 chapters: history of vaccine process development; the production of Plasmid DNA vaccine in Escherichia coli; fungal expression systems for vaccine production; novel expression systems for vaccine production; viral vaccines purification; protein subunit vaccine purification; conjugate vaccine production technology; stabilization and formulation of vaccines; lyophilization in vaccine processes; strategies for heat-stable vaccines; production and characterization of aluminum-containing adjuvants; the biologics license application (BLA) in common technical document (CTD) format; the original new drug application (investigational new drug); facility design for vaccine manufacturing; vaccine production economics. Annotation ©2015 Ringgold, Inc., Portland, OR (protoview.com)

Vaccine Manufacturing and Production is an invaluable reference on how to produce a vaccine - from beginning to end - addressing all classes of vaccines from a processing, production, and regulatory viewpoint. It will provide comprehensive information on the various fields involved in the production of vaccines, from fermentation, purification, formulation, to regulatory filing and facility designs. In recent years, there have been tremendous advances in all aspects of vaccine manufacturing. Improved technology and growth media have been developed for the production of cell culture with high cell density or fermentation. Vaccine Manufacturing and Production will serve as a reference on all aspects of vaccine production by providing an in-depth description of the available technologies for making different types of vaccines and the current thinking in facility designs and supply issues. This book will provide insight to the issues scientists face when producing a vaccine, the steps that are involved, and will serve as a reference tool regarding state-of-the-art vaccine manufacturing technologies and facility set-up.

Highlights include:

  • Comprehensive coverage of vaccine production : from a process point of view- fermentation to purification to formulation developments; from a production point of view - from facility design to manufacturing; and from a regulatory point of view - requirements from government agencies
  • Authors from different major pharmaceutical and biotechnology companies
  • Describes the challenges and issues involved in vaccine production and manufacturing of the different classes of vaccines, an area not covered by other books currently on the market
Acknowledgments vii
Preface ix
Contributors xi
1 History of Vaccine Process Development
1(24)
Narahari S. Pujar
Sangeetha L. Sagar
Ann L. Lee
2 The Production of Plasmid DNA Vaccine in Escherichia coli: A Novel Bacterial-Based Vaccine Production Platform
25(26)
Michel Chartrain
3 Fungal Expression Systems for Vaccine Production
51(30)
Karl Melber
Volker Jenzelewski
Roland Weyhenmeyer
Zbigniew Janowicz
4 Novel Expression Systems for Vaccine Production
81(16)
Shailaja Rabindran
Vidadi Yusibov
5 Viral Vaccines Purification
97(84)
Bernd Kalbfuss-Zimmermann
Udo Reichl
6 Protein Subunit Vaccine Purification
181(36)
Yan-ping Yang
Tony D'Amore
7 Conjugate Vaccine Production Technology
217(20)
Sudha Chennasamudram
Willie F. Vann
8 Stabilization and Formulation of Vaccines
237(26)
Timothy S. Priddy
C. Russell Middaugh
9 Lyophilization in Vaccine Processes
263(24)
Alexis Wasserman
Ranjit Sarpal
Bret R. Phillips
10 Strategies for Heat-Stable Vaccines
287(32)
Satoshi Ohtake
David Lechuga-Ballesteros
Vu Truong-Le
Eric J. Patzer
11 Production and Characterization of Aluminum-Containing Adjuvants
319(28)
Stanley L. Hem
Cliff T. Johnston
12 The Biologics License Application (BLA) in Common Technical Document (CTD) Format
347(26)
R.S. Robin Robinett
13 The Original New Drug Application (Investigational New Drug)
373(20)
R.S. Robin Robinett
14 Facility Design for Vaccine Manufacturing-Regulatory, Business, and Technical Considerations and A Risk-Based Design Approach
393(20)
Anand Ekambaram
Abraham Shamir
15 Vaccine Production Economics
413(24)
Andrew Sinclair
Peter Latham
Index 437
EMILY P. WEN, PhD, is currently a Research Fellow at the Merck Research Laboratory in the department of Vaccine Process Development. Dr. Wen has led process developments for several major vaccine products from Phase I to Phase III clinical trials, including vaccines against hepatitis B, Haemophilus influenzae type b, Pneumococcal, Meningococcal, and Group B Streptococcus.

RONALD ELLIS, PhD, is Chief Technology Officer at FutuRx Ltd in Israel. Dr. Ellis has more than 30 years of industry experience in line and senior management in many companies, including roles as project leader and champion of projects that resulted in five licensed vaccines which accrue ~$4B in annual sales. He is the founding and incumbent Editor-in-Chief of the MedLine-/PubMed-indexed journal Human Vaccines & Immunotherapeutics.

NARAHARI S. PUJAR, PhD, MBA, is currently an Executive Director and Integrated Product Leader in the Vaccine Business Line at Merck & Co., Inc. Dr. Pujar has contributed to a variety of vaccines and biologics products and product candidates. He is an active member of the American Chemical Society and was the past chair of the Division of Biochemical Technology.